Others titles

  • EMA European Public Assessment Reports
  • European Medicines Agency EPARs

Keywords

  • European Medicines Agency
  • EMA Assessment Reports
  • Centralised Authorization Procedure
  • EMA Clinical DATA

European Public Assessment Reports

The European Medicines Agency (EMA) publishes a European Public Assessment Report (EPAR) for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
EPARs are full scientific assessment reports of medicines authorized at a European Union level.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Data Library End User License Agreement (“EULA”) applies to academic researchers, educators, and students using any product of John Snow Labs in John Snow Labs’ Data Library as defined below (hereinafter referred to “you”). This EULA is between you and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading and/or using (as applicable) Data Library of John Snow Labs (as defined below), you automatically agree to be bound by, and use it in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE DOWNLOADING OR USING DATA LIBRARY.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of Data Library after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“Data Library” means a data library provided by John Snow Labs and located at https://www.johnsnowlabs.com/marketplace/;

“Website” means https://www.johnsnowlabs.com being owned and operated by John Snow Labs.

Important Notice

By downloading and using any product from the Data Library, you acknowledge that the use of Data Library can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use Data Library for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Data Library can be used by an individual.

In the event you have entered into a separate written agreement with John Snow Labs regarding Data Library that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all

License Granted

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, revocable, license to download, access to, modify, and use of, Data Library worldwide (subject to applicable export laws) during the term of this EULA (as described below) under the following conditions:

  • The license can be used solely for research, private study and personal use of Data Library for unlimited period, or unless terminated under this EULA.were made;
  • This license is personal to you and is limited by all terms and conditions set forth in this EULA;
  • The license is granted as a non-commercial, attribution, share-alike and no-derivate-work license as more detailed below;
  • Under the attribution license, you must give the appropriate name of the creator and a copyright notice of John Snow Labs, provide link to this license and indicate if changes
  • Under the share-alike license, you can distribute modified works only under a license identical to this EULA;
  • Under the no-derivate-work license, you can perform only verbatim copies of Data Library, not derivate works or remixes based on it;
  • If the license is used for academic research purpose, the publication shall be made under the open-access, open-source and open-data license.

You can download any dataset from the Data Library from the Website.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Data Library, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Data Library is protected by applicable intellectual property laws, including United States copyright law and international treaties.

John Snow Labs is entitled to revoke the license granted at any time at its sole discretion.

License Restrictions

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of Data Library. You are responsible for end users’ use of your content and Data Library. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and Data Library by such end user.

License Restrictions

You will access or use our Data Library solely via John Snow Labs’ Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. you cannot reproduce, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of Data Library or its technological features or measures;
  2. you cannot rent, lease, sell, resell, loan, distribute, or sublicense access to any of Data Library;
  3. you cannot circumvent or disable any security or technological features or measures of Data Library;
  4. you cannot use our intellectual property rights without our express prior written authorization or in violation of this EULA;
  5. you cannot use Data Library with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of Data Library;
  6. you cannot copy, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on Data Library (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  7. you cannot use any automated tool (e.g., robots, spiders) to access or use Data Library, or to store, copy, modify, distribute, or resell any Content;
  8. you cannot circumvent or disable any rights management, usage rules, or other security features of Data Library;
  9. you cannot use Data Library in a manner that overburdens, or that threatens the integrity, performance, or availability of, Data Library; or
  10. you cannot remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

If you breach any of this EULA, the above license will terminate automatically.

Fees and Taxes

This license is for non-commercial use. If you wish to use our Data Library for commercial use, please contact us at support@JohnSnowLabs.com.

Support and Updates

Under this EULA, support services are excluded.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Term and Termination

This EULA will become effective as of the date of your order of Data Library and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use Data Library, if you or your end user’s use of Data Library:

  1. is in breach of this EULA;
  2. poses a security risk to Data Library;
  3. could adversely impact our systems, Data Library or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use Data Library, if you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

You will cease use of Data Library during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Access to Data Library

We do not provide you with the equipment to access Data Library. You are responsible for all fees charged by third parties related to your access and use of Data Library (e.g., charges by Internet service providers).

You are responsible for monitoring your use of Data Library, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of Data Library for auditing purposes.

You also certify that you are legally permitted to use Data Library, and take full responsibility for the selection and use of Data Library. This EULA is void where prohibited by law, and the right to use Data Library is revoked in such jurisdictions. John Snow Labs makes no claim that Data Library may be lawfully used outside of the United States. If you use Data Library from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Data Library may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using Data Library (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using Data Library, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

Data Library is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to Data Library or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of Data Library or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on Data Library are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of Data Library, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in Data Library are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF DATA LIBRARY IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of Data Library; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of Data Library will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Data Library. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about Data Library or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

A European public assessment report (EPAR) is published for every human or veterinary medicine application that has been granted or refused a marketing authorization. This follows an assessment by the EMA of an application submitted by a pharmaceutical company in the framework of the Central authorization of medicines.
An EPAR provides public information on a medicine, including how it was assessed by the EMA.
The EPAR is referred to in Article 13(3) of Regulation (EC) No 726/2004, which requires the EMA to publish a public assessment report for each centrally authorized medicine together with a public-friendly summary.
The EMA has developed the EPAR concept over time to ensure that it delivers a usable, transparent and appropriately detailed body of information. The EPAR content and structure have therefore evolved over time and may be further developed in future.
An important role of the EPAR is to reflect the scientific conclusions of the relevant EMA committee at the end of the assessment process, providing the grounds for the committee opinion on whether or not to approve an application.
Under the centralized authorization procedure, pharmaceutical companies submit a single marketing-authorization application to EMA. This allows the marketing-authorization holder to market the medicine and make it available to patients and healthcare professionals throughout the EU on the basis of a single marketing authorization.
EMA’s Committee for Medicinal products for Human Use (CHMP) or Committee for Medicinal products for Veterinary Use (CVMP) carry out a scientific assessment of the application and give a recommendation on whether the medicine should be marketed or no.
An orphan designation allows a pharmaceutical company to benefit from incentives from the European Union to develop a medicine for a rare disease, such as reduced fees and protection from competition once the medicine is placed on the market. Applications for orphan designation are examined by the COMP, which adopts an opinion that is forwarded to the European Commission. The European Commission then decides whether to grant an orphan designation for the medicine in question.

About this Dataset

Data Info

Date Created

2011

Last Modified

2020-07-20

Version

2020-07-20

Update Frequency

Irregular

Temporal Coverage

N/A

Spatial Coverage

European Economic Area Countries

Source

John Snow Labs; European Medicines Agency (EMA);

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

European Medicines Agency, EMA Assessment Reports, Centralised Authorization Procedure, EMA Clinical DATA

Other Titles

EMA European Public Assessment Reports, European Medicines Agency EPARs

Data Fields

Name Description Type Constraints
CategoryValue: Human, Veterinarystringrequired : 1
Medicine_NameMedicine Namestringrequired : 1
Therapeutic_AreaProduct therapeutic areastring-
Common_NameProduct common namestring-
Active_SubstanceActive substance namestringrequired : 1
Product_NumberThe product numberstringrequired : 1
Is_Patient_SafetyIndicate if the product is concerned by a patient safety informationbooleanrequired : 1
Authorisation_StatusCurrent product statusstringenum : Array ( [0] => Authorised [1] => Refused [2] => Suspended [3] => Withdrawn ) required : 1
ATC_CodeAnatomical Therapeutic Chemical (ATC) codestring-
Is_Additional_MonitoringIndicate if the product is under additional monitoringbooleanrequired : 1
Is_GenericIndicate if the product is a genericbooleanrequired : 1
Is_BiosimilarIndicate if the product is a biosimilarbooleanrequired : 1
Is_Condition_ApprovalIndicate if the product is approved under specific conditions. Sometimes, the CHMP recommends that a medicine be given ‘conditional approval’. This happens when the Committee has based its positive opinion on data which, while not yet comprehensive, indicate that the medicine’s benefits outweigh its risks.booleanrequired : 1
Is_Exceptional_CircumstanceIndicate if there were "exceptional circumstances" concerning the approval of this medicine. This happens when the applicant can show that they are unable to provide comprehensive data on the efficacy and safety of the medicine for which authorisation is being sought, due to the rarity of the condition it is intended for, limited scientific knowledge in the area concerned, or ethical considerations involved in the collection of such data.booleanrequired : 1
Is_Accelerated_AssessmentIndicate this medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210.booleanrequired : 1
Is_OrphanIndicate if the product has an "orphan designation" which means that it is used to treat life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the European Union, or are medicines which, for economic reasons, would be unlikely to be developed without incentives.booleanrequired : 1
Marketing_Authorization_DateAuthorization datedate-
Refusal_DateDate of refusal of marketing authorisationdate-
Marketing_Authorization_HolderMarketing authorization holder namestring-
Human_Pharmacotherapeutic_GroupHuman pharmacotherapeutic group namestring-
Vet_Pharmacotherapeutic_GroupVeterinary pharmacotherapeutic group namestring-
Date_of_OpinionOpinion datedate-
Decision_DateDate of decisiondate-
Revision_NumberRevision numberintegerlevel : Ratio
IndicationProduct indicationstring-
SpeciesVeterinary speciesstring-
ATC_Vet_CodeAnatomical Therapeutic Chemical (ATC) veterinary codestring-
First_PublishedDate of first publicationdate-
Revision_DateDate of revisiondate-
EMA_LinkURL of the product at EMA websitestring-

Data Preview

CategoryMedicine NameTherapeutic AreaCommon NameActive SubstanceProduct NumberIs Patient SafetyAuthorisation StatusATC CodeIs Additional MonitoringIs GenericIs BiosimilarIs Condition ApprovalIs Exceptional CircumstanceIs Accelerated AssessmentIs OrphanMarketing Authorization DateRefusal DateMarketing Authorization HolderHuman Pharmacotherapeutic GroupVet Pharmacotherapeutic GroupDate of OpinionDecision DateRevision NumberIndicationSpeciesATC Vet CodeFirst PublishedRevision DateEMA Link
HumanNepextoArthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Arthritis, Psoriatic, Spondylarthropathies, Spondylitis, Ankylosing, PsoriasisetanerceptetanerceptEMEA/H/C/004711FalseAuthorisedL04AB01TrueFalseTrueFalseFalseFalseFalse2020-05-20Mylan IRE Healthcare LimitedImmunosuppressants2020-03-262020-07-071Rheumatoid arthritisNepexto in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.Nepexto can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Nepexto is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Nepexto, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.Juvenile idiopathic arthritisTreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.Etanercept has not been studied in children aged less than 2 years.Psoriatic arthritisTreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.Axial spondyloarthritisAnkylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Non-radiographic axial spondyloarthritis Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).Plaque psoriasisTreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).Paediatric plaque psoriasisTreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.2020-06-042020-07-24https://www.ema.europa.eu/en/medicines/human/EPAR/nepexto
HumanYentreveUrinary Incontinence, Stressduloxetineduloxetine hydrochlorideEMEA/H/C/000545FalseAuthorisedN06AX21FalseFalseFalseFalseFalseFalseFalse2004-08-11Eli Lilly Nederland B.V.Psychoanaleptics, 2020-06-1126Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI)., 2016-12-192020-07-24https://www.ema.europa.eu/en/medicines/human/EPAR/yentreve
HumanFirmagonProstatic NeoplasmsdegarelixdegarelixEMEA/H/C/000986FalseAuthorisedL02BX02FalseFalseFalseFalseFalseFalseFalse2009-02-17Ferring Pharmaceuticals A/SEndocrine therapy2020-07-0915Firmagon is a gonadotrophin-releasing-hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.2018-07-252020-07-24https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon
HumanTygacilBacterial Infections, Skin Diseases, Bacterial, Soft Tissue InfectionstigecyclineTigecyclineEMEA/H/C/000644FalseAuthorisedJ01AA12FalseFalseFalseFalseFalseFalseFalse2006-04-24Pfizer Europe MA EEIGAntibacterials for systemic use, 2020-05-1431Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections:, , Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections, Complicated intra-abdominal infections (cIAI), Tygacil should be used only in situations where other alternative antibiotics are not suitable., , Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents., 2018-07-302020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/tygacil
HumanAtriplaHIV Infectionsefavirenz / emtricitabine / tenofovir disoproxilefavirenz, emtricitabine, tenofovir disoproxil fumarateEMEA/H/C/000797FalseAuthorisedJ05AR06FalseFalseFalseFalseFalseFalseFalse2007-12-13Gilead Sciences Ireland UCAntivirals for systemic use, 2020-06-1134Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen., , The demonstration of the benefit of Atripla is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Atripla., , No data are currently available from clinical studies with Atripla in treatment-naive or in heavily pretreated patients., , No data are available to support the combination of Atripla and other antiretroviral agents., 2018-07-252020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/atripla
HumanInhixaVenous Thromboembolismenoxaparin sodiumenoxaparin sodiumEMEA/H/C/004264FalseAuthorisedB01AB05TrueFalseTrueFalseFalseFalseFalse2016-09-15Techdow Pharma Netherlands B.V. Antithrombotic agents, 2016-07-212020-06-2516Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.2018-06-222020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa
HumanSialanarSialorrheaglycopyrroniumGlycopyrronium bromideEMEA/H/C/003883FalseAuthorisedA03AB02FalseFalseFalseFalseFalseFalseFalse2016-09-15Proveca Pharma LimitedDrugs for functional gastrointestinal disorders2020-04-305Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders., 2017-05-112020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar
HumanKivexaHIV Infectionsabacavir / lamivudineabacavir, lamivudineEMEA/H/C/000581FalseAuthorisedJ05AR02FalseFalseFalseFalseFalseFalseFalse2004-12-16ViiV Healthcare BVAntivirals for treatment of HIV infections, combinations, Antivirals for systemic use, 2020-06-1132Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg., , Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele., 2018-01-252020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
HumanJakaviMyeloproliferative Disordersruxolitinibruxolitinib (as phosphate)EMEA/H/C/002464FalseAuthorisedL01XE18FalseFalseFalseFalseFalseFalseFalse2012-08-23Novartis Europharm LimitedAntineoplastic agents, 2020-06-1120Myelofibrosis (MF)Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.2018-05-222020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi
HumanIbandronic acid AccordWounds and Injuries, Breast Diseases, Neoplastic Processes, Calcium Metabolism Disorders, Neoplasms by Site, Water-Electrolyte Imbalanceibandronic acidibandronic acidEMEA/H/C/002638FalseAuthorisedM05BA06FalseTrueFalseFalseFalseFalseFalse2012-11-18Accord Healthcare S.L.U.Drugs for treatment of bone diseases2020-07-0810Ibandronic acid is indicated in adults for, , Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases., Treatment of tumour induced hypercalcaemia with or without metastases., Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1)., , A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established., 2017-09-182020-07-23https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-accord